Astream/Astream Provides "Safe and Effective Intraocular Pressure Reduction"
Microt Co., Ltd., an ophthalmic medical device company, announced that its glaucoma MIGS implant medical device, "Aistream," received approval from the Ministry of Food and Drug Safety on September 15, 2023, and will be launched domestically in October 2023.
Microt started as a medical device venture company in 2019 and is engaged in research and development of various products related to glaucoma and ophthalmology. Additionally, in May 2023, it was selected as one of 51 "Baby Unicorn" companies with high potential to grow into a global unicorn, overcoming a competition rate of 6:1.
Glaucoma is a disease in which the optic nerve inside the eye gradually weakens, causing the visual field to narrow progressively. Among various causes, elevated intraocular pressure mechanically compresses the optic nerve, which is known to be the primary cause of the onset and worsening of glaucoma.
The upcoming "Aistream" product is a minimally invasive glaucoma surgery (MIGS) device developed over a long period to provide treatment options for patients who have not achieved sufficient effects from existing glaucoma treatments and surgeries.
"Aistream" is a very small, 6mm-long mini implant designed to provide intraocular pressure reduction effects and is made using "medical-grade silicone." Silicone is a material with high biocompatibility and biosafety, widely used for a long time in various fields such as orthopedics.
Microt announced plans to obtain FDA and CE (MDR) approvals following the domestic launch of "Aistream" and is conducting various projects for overseas expansion.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
